GeneDx price target raised to $95 from $70 at Craig-Hallum

Craig-Hallum raised the firm’s price target on GeneDx (WGS) to $95 from $70 and keeps a Buy rating on the shares. The firm remains positive following a significant Q3 beat and raise and achievement of adjusted Net Income profitability several quarters sooner than it had expected.